Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 12:40PM GMT
Release Date Price: R$26.37
Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD

Hi, I'm Louise Chen, the large-cap biopharma analyst here at Cantor. Thank you for joining us today for a virtual fireside chat with Eli Lilly. Lilly is one of the top-performing pharma companies in the sector with a robust portfolio of fast-growing products and a pipeline of first-in-class and/or best-in-class drugs. We think the company's earnings profile continues to look favorable when compared to those of its peers. Its margin expansion profile represents one of the strongest in the pharma industry, with a potential for mid-teens EPS growth. Lilly is entering a period of earnings growth, unencumbered by large loss of exclusivities and bolstered by multiple pipeline readouts of its first-in-class and/or best-in-class compounds. Therefore, we are thrilled to have with us today, CFO, Josh Smiley, to talk about the business.

Questions & Answers

Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot